These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2691000)

  • 1. Tardive dystonia. The benefits of time.
    Cooper SJ; Doherty MM; King DJ
    Br J Psychiatry; 1989 Jul; 155():113-5. PubMed ID: 2691000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
    Sachdev P; Tang WM
    Aust N Z J Psychiatry; 1992 Dec; 26(4):666-70. PubMed ID: 1362053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive oculogyric crisis and obsessional thoughts.
    Sachdev P
    Br J Psychiatry; 1991 May; 158():720-1. PubMed ID: 1860035
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
    Kane JM; Rifkin A; Woerner M; Reardon G; Sarantakos S; Schiebel D; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1983 Aug; 40(8):893-6. PubMed ID: 6347119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
    Curson DA; Barnes TR; Bamber RW; Platt SD; Hirsch SR; Duffy JC
    Br J Psychiatry; 1985 May; 146():469-74. PubMed ID: 3893599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluphenazine and tardive dyskinesia.
    Perényi A; Arató M
    Arch Gen Psychiatry; 1984 Jul; 41(7):727. PubMed ID: 6732436
    [No Abstract]   [Full Text] [Related]  

  • 8. Facial dyskinesia: a 16-year follow-up study.
    McClelland HA; Metcalfe AV; Kerr TA; Dutta D; Watson P
    Br J Psychiatry; 1991 May; 158():691-6. PubMed ID: 1677601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
    Russell N; Landmark J; Merskey H; Turpin T
    Can J Psychiatry; 1982 Nov; 27(7):593-6. PubMed ID: 7172160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depot fluphenazine: risk/benefit ratio.
    Glazer WM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics.
    Galdi J; Bonato RR
    Can J Psychiatry; 1988 Dec; 33(9):816-8. PubMed ID: 2905632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind placebo-controlled, crossover study.
    Karniol IG; Portela W
    Braz J Med Biol Res; 1982 Dec; 15(6):389-94. PubMed ID: 6135468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
    Marder SR; Van Putten T; Mintz J; Lebell M; McKenzie J; May PR
    Arch Gen Psychiatry; 1987 Jun; 44(6):518-21. PubMed ID: 3555385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and benefits of two doses of fluphenazine.
    Marder SR; Van Putten T; Mintz J; McKenzie J; Lebell M; Faltico G; May PR
    Arch Gen Psychiatry; 1984 Nov; 41(11):1025-9. PubMed ID: 6437365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie R; Mackie M; Morrison D; Kidd J
    Br J Psychiatry; 1982 Mar; 140():280-6. PubMed ID: 7093596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute dystonia during fixed-dose neuroleptic treatment.
    Singh H; Levinson DF; Simpson GM; Lo ES; Friedman E
    J Clin Psychopharmacol; 1990 Dec; 10(6):389-96. PubMed ID: 2286708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propranolol, anxiety, and tardive dyskinesia.
    Bacher NA; Lewis HA
    J Clin Psychiatry; 1983 May; 44(5):196. PubMed ID: 6133849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.